文献速递MDS 与骨髓增殖性肿瘤

帕博利珠单抗治疗晚期骨髓增殖性肿瘤的2期研究

PD-1 inhibition in advanced myeloproliferative neoplasms.
PubMed 文献 · Blood Adv · 2021-01-01

这项多中心、开放标签、2期单臂研究评估了帕博利珠单抗在不适合或既往接受过芦可替尼的中危-2及以上原发性、ET后或PV后骨髓纤维化患者中的疗效。研究采用Simon两阶段设计,共入组10例患者,治疗耐受性良好但无客观临床反应,研究在第一阶段完成后终止。免疫分析显示免疫微环境改变提示T细胞反应改善,但未转化为临床疗效。

要点

  • 帕博利珠单抗在晚期骨髓纤维化中耐受性良好但无客观临床反应
  • 免疫分析显示T细胞反应改善但未转化为临床疗效
  • 单药PD-1抑制可能不足以逆转骨髓纤维化的多重免疫抑制机制

核心结论

  • 帕博利珠单抗单药治疗晚期骨髓纤维化耐受性良好,但无客观临床反应,研究在第一阶段完成后终止。
  • 免疫分析显示免疫微环境改变提示T细胞反应改善,但未转化为临床疗效,提示可能需要联合免疫治疗。

研究设计与样本

  • 多中心、开放标签、2期单臂研究,采用Simon两阶段设计。
  • 共入组10例DIPSS中危-2及以上原发性、ET后或PV后骨髓纤维化患者,不适合或既往接受过芦可替尼。
  • 5例患者有JAK2V617F突变,2例有CALR突变,6例有额外突变;大多数患者既往接受过芦可替尼。

主要发现

  • 帕博利珠单抗治疗耐受性良好,但无客观临床反应,研究在第一阶段完成后关闭。
  • 流式细胞术、T细胞受体测序和血浆蛋白质组学显示患者免疫微环境发生变化,提示T细胞反应改善。

临床怎么用

  • PD-1单药抑制在晚期骨髓纤维化中未显示临床疗效,不支持单独使用。
  • 免疫微环境改变提示联合免疫治疗策略可能必要,但需进一步研究验证。

局限性

  • 样本量小(共10例),研究在第一阶段完成后提前终止。
  • 单臂设计,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelofibrosis (MF) is a clonal stem cell neoplasm characterized by abnormal JAK-STAT signaling, chronic inflammation, cytopenias, and risk of transformation to acute leukemia. Despite improvements in the therapeutic options for patients with MF, allogeneic hematopoietic stem cell transplantation remains the only curative treatment. We previously demonstrated multiple immunosuppressive mechanisms in patients with MF, including increased expression of programmed cell death protein 1 (PD-1) on T cells compared with healthy controls. Therefore, we conducted a multicenter, open-label, phase 2, single-arm study of pembrolizumab in patients with Dynamic International Prognostic Scoring System category of intermediate-2 or greater primary, post-essential thrombocythemia or post-polycythemia vera myelofibrosis that were ineligible for or were previously treated with ruxolitinib. The study followed a Simon 2-stage design and enrolled a total of 10 patients, 5 of whom had JAK2V617mutation, 2 had CALR mutation, and 6 had additional mutations. Most patients were previously treated with ruxolitinib. Pembrolizumab treatment was well tolerated, but there were no objective clinical responses, so the study closed after the first stage was completed. However, immune profiling by flow cytometry, T-cell receptor sequencing, and plasma proteomics demonstrated changes in the immune milieu of patients, which suggested improved T-cell responses that can potentially favor antitumor immunity. The fact that these changes were not reflected in a clinical response strongly suggests that combination immunotherapeutic approaches rather than monotherapy may be necessary to reverse the multifactorial mechanisms of immune suppression in myeloproliferative neoplasms. This trial was registered at www.clinicaltrials.gov as #NCT03065400.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hobbs G, Cimen Bozkus C, Moshier E, et al. PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv. 2021. PMID: 34581778. doi:10.1182/bloodadvances.2021005491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。